Advertisement


Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Issues in Oncology
Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement



Dec
02
Today In Oncology
Lung Cancer Screening May Increase Long-Term Survival Rate
High Deductibles May Discourage Patients From Receiving Additional Testing After an Abnormal Mammogram
Study Finds Americans Have a Low Awareness of the Link Between Alcohol Use and Increased Cancer Risk
Does CBD Oil Improve Symptom Distress in Patients With Advanced Cancer Receiving Palliative Care
Incidence of Cervical Cancer in Women in the United States 2001 to 2019
View More 
Advertisement
© 2022 HSP News Service, L.L.C.
Designed by Harborside